Immune system decline, dysfunction, and senescence are commonly observed in the setting of cancer progression, with a pronounced restriction amongst CD8+ T effector cells, which are known for their capacity to mediate tumor regression (1). The gene discussed is CD8A; the disease is neoplasm.